On March 13, 2025 Immorta Bio Inc., a scientific longevity company focused on "Treating Diseases of Aging and Treating Aging as Disease," reported that its Chairman and CEO, Dr. Boris Reznik, presented the latest findings from its SenoVax Program at the LSX Investival Showcase on March 11th at the Miami Beach Convention Centre (Press release, Immorta Bio, MAR 13, 2025, View Source [SID1234651137]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The presentation disclosed advancements in the Company’s oncology pipeline, highlighting animal studies showing the regression of brain, lung, skin, pancreas, and breast cancers by SenoVax, the Company’s lead product. Additionally, cellular mechanisms by which this "longevity therapeutic" targets a broad range of cancers were discussed.
"It has been widely demonstrated that senescent cells play a critical role in initiating, promoting and protecting cancer," said Dr. Thomas Ichim, President and Chief Scientific Officer of the Company. "By amplifying the body’s natural immunological activities to kill senescent cells, SenoVax induces regression of tumors."
The Company, together with the University of California San Diego, George Washington University, Calidi Biosciences, and Cedars Sinai, demonstrated in a peer-reviewed publication that SenoVax kills cancer in part by inducing antibody and T cell responses that eliminate senescent cells¹.
"We are developing multiple programs focused on radical extension of human healthspan including our senolytic immunotherapy platform," said Dr. Boris Reznik, Chairman and CEO of Immorta Bio. "Our development strategy is to apply longevity-associated technologies to address unmet medical needs that can provide answers in months not decades."